High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
143.60M
+116.23%
-0.130
-78.33%
148.83M
+89.99%
-0.240
-62.5%
172.63M
+68.15%
0.480
-200%
Estimates Revision
The market is revising Upward the revenue expectations for Tarsus Pharmaceuticals, Inc. (TARS) for FY2025, with the revenue forecasts being adjusted by 4.14% over the past three months. During the same period, the stock price has changed by 41.99%.
Revenue Estimates for FY2025
Revise Upward
+4.14%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.48%
In Past 3 Month
Stock Price
Go Up
+41.99%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast TARS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 80.75 USD with a low forecast of 51.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.830
Low
51.00
Averages
80.75
High
100.00
Current: 81.830
Low
51.00
Averages
80.75
High
100.00
Mizuho
initiated
$100
2025-11-20
Reason
Mizuho
Price Target
$100
2025-11-20
initiated
Reason
Mizuho initiated coverage of Tarsus Pharmaceuticals with an Outperform rating and $100 price target. Tarsus is a commercial stage, ophthalmology-focused company that markets Xdemvy, the only approved treatment for Demodex blepharitis, the analyst tells investors in a research note. The firm projects peak Xdemvy sales in DB of over $2B. Mizuho's physician survey supports the bullish view, it says.
Goldman Sachs
Andrea Tan
Neutral
maintain
$45 -> $51
2025-11-06
Reason
Goldman Sachs
Andrea Tan
Price Target
$45 -> $51
2025-11-06
maintain
Neutral
Reason
Goldman Sachs analyst Andrea Tan raised the firm's price target on Tarsus Pharmaceuticals to $51 from $45 and keeps a Neutral rating on the shares.
H.C. Wainwright
Neutral
maintain
$72 -> $88
2025-10-20
Reason
H.C. Wainwright
Price Target
$72 -> $88
2025-10-20
maintain
Neutral
Reason
H.C. Wainwright raised the firm's price target on Tarsus Pharmaceuticals to $88 from $72 and keeps a Neutral rating on the shares. The firm upped its sales estimates for Xdemvy ahead of the Q3 results based on its conviction in the launch trajectory.
Oppenheimer
Oppenheimer
Outperform
upgrade
$72 -> $75
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$72 -> $75
2025-06-02
upgrade
Outperform
Reason
Oppenheimer assumed coverage of Tarsus Pharmaceuticals with an Outperform rating with a price target of $75, up from $72. The firm notes the company reported Q1 2025 topline of $78.3M, beating consensus estimates, with volume of about 72K surpassing guidance. XDEMVY's momentum remains strong, driven by its growth initiatives. Management highlighted encouraging shifts in prescribing patterns from monthly to weekly prescribing, noting that thousands of target ECPs remain below capacity. Oppenheimer is encouraged by broad commercial, Medicare, and Medicaid coverage. With sales force expansion, coverage, DTC, and evidence generation progressing, plus a strengthened balance sheet, the firm believes XDEMVY's momentum is well-poised to grow.
H.C. Wainwright
Oren Livnat
initiated
$72
2025-05-27
Reason
H.C. Wainwright
Oren Livnat
Price Target
$72
2025-05-27
initiated
Reason
H.C. Wainwright analyst Oren Livnat assumed coverage of Tarsus Pharmaceuticals with a Buy rating and $72 price target. The firm likes the company's Xdemvy impetus in Demodex blepharitis. Xdemvy represents the first and only FDA approved therapy to treat Demodex blepharitis, the analyst tells investors in a research note.
Jefferies
Anthony Petrone
Strong Buy
Maintains
$54 → $58
2025-03-06
Reason
Jefferies
Anthony Petrone
Price Target
$54 → $58
2025-03-06
Maintains
Strong Buy
Reason
Jefferies raised the firm's price target on Tarsus Pharmaceuticals to $58 from $54 and keeps a Buy rating on the shares. The firm says it is surprised the stock is down over 20% year-to-date given the impressive Q4 and FY24 results, which outperformed expectations every quarter; its outlook for about 100% revenue growth in 2025; and the company quickly approaching cash flow breakeven. As a result, Jefferies does not think the shares in the mid-40s adequately reflect the successful Xdemvy launch plus the path to profitability, which it believes is 2025/2026.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Tarsus Pharmaceuticals Inc (TARS.O) is 97.42, compared to its 5-year average forward P/E of 110.02. For a more detailed relative valuation and DCF analysis to assess Tarsus Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
110.02
Current PE
97.42
Overvalued PE
712.28
Undervalued PE
-492.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
3.40
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
45.91
Undervalued EV/EBITDA
-39.11
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
18.24
Current PS
0.00
Overvalued PS
31.67
Undervalued PS
4.80
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 525.94% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 987.14% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 525.94% over the last month.
Sold
Bought
TARS News & Events
Events Timeline
(ET)
2025-11-04
16:14:42
Tarsus Pharmaceuticals announces Q3 earnings per share of 30 cents, below consensus estimate of 33 cents.
2025-08-06 (ET)
2025-08-06
17:10:47
Tarsus Pharmaceuticals reports Q2 EPS (48c), consensus (36c)
2025-05-05 (ET)
2025-05-05
06:33:33
Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/de908023940b7380e2cacbc0e1e29686929495a912e8edc36536befc28c9c22e.jpg)
Preview
9.0
11-19NASDAQ.COMFrom Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/0a49c462cabb4a96567ec8cd0e8dd487493d4f2e19b20c6a0ef31c59126dd421.jpg)
Preview
9.5
11-05NASDAQ.COMTarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/seekingalpha.png)
Preview
7.0
11-05SeekingAlphaTarsus Sets Q4 Sales Goal of $140M–$145M Amidst Increased XDEMVY Adoption and Pipeline Development
Sign Up For More News
People Also Watch
FAQ
What is Tarsus Pharmaceuticals Inc (TARS) stock price today?
What is Tarsus Pharmaceuticals Inc (TARS)'s business?
What is the price predicton of TARS Stock?
What is Tarsus Pharmaceuticals Inc (TARS)'s revenue for the last quarter?
What is Tarsus Pharmaceuticals Inc (TARS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Tarsus Pharmaceuticals Inc (TARS)'s fundamentals?
How many employees does Tarsus Pharmaceuticals Inc (TARS). have?